enVVeno Medical Corporation (NVNO)
NASDAQ: NVNOHealthcareMedical DevicesUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
NVNO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.68M
- EPS (TTM)
- -$25.15
- Dividend yield
- None
- 52-week range
- 7.01 – 30.80
- Day range
- 8.06 – 8.48
- Volume / Avg
- 6.51K / 23.71K
- Beta
- —
- Shares outstanding
- 694.83K
- Next earnings
- Oct 30, 2026
52-week range
NVNO stock today
Shares of enVVeno Medical (NVNO) finished lower on Oct 8 at $8.18, a drop of 2.68% or $0.225 per share, versus the S&P 500's 0.47% decline. Trading was light, with 6.51K shares changing hands, about 27% of the average daily volume. Shares are 73.5% below their 52-week high of $30.80 and 16.6% above the 52-week low of $7.01, near the bottom of the past year's range.
enVVeno Medical has posted a net loss over the last twelve months (EPS of -$25.15), so its P/E ratio is not meaningful. enVVeno Medical's next earnings report is expected on Oct 30, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About enVVeno Medical
Company profileenVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh.
- Sector
- Healthcare
- Industry
- Medical Devices
- CEO
- Mr. Robert A. Berman
- Headquarters
- Irvine, CA
- Employees
- 33
- IPO year
- 2018
- Website
- envveno.com
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$30.00+266.97%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 30, 2026
enVVeno Medical peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ICCMIceCure Medical Ltd. | 1.13 | -1.74% | $5.24M | vs NVNO |
| AMIXAutonomix Medical Inc. | 3.13 | -8.21% | $6.13M | vs NVNO |
| INBSIntelligent Bio Solutions Inc. | 1.57 | -1.26% | $5.21M | vs NVNO |
| VVOSVivos Therapeutics Inc. | 0.1495 | -0.99% | $5.02M | vs NVNO |
| TRIBTrinity Biotech plc ADR | 6.04 | -10.91% | $4.91M | vs NVNO |
| AIDX20/20 Biolabs Inc. | 0.379 | +10.33% | $4.84M | vs NVNO |
| VNRXVolitionRX Limited | 0.2194 | -2.92% | $6.60M | vs NVNO |
| WOKWORK Medical Technology Group LTD Class A | 1.52 | -1.94% | $6.79M | vs NVNO |
Indexes, lists and sector
Appears in lists
enVVeno Medical stock FAQ
What is enVVeno Medical's stock price today?
NVNO last traded at $8.18 as of Oct 8, 4:00 PM EDT, down 2.68% on the day. Prices are delayed at least 15 minutes.
When is enVVeno Medical's next earnings date?
enVVeno Medical is expected to report earnings on Friday, October 30, 2026.
Who is enVVeno Medical's CEO?
Mr. Robert A. Berman is the chief executive officer of enVVeno Medical Corporation, which has about 33 employees.
What is the NVNO 52-week high?
The 52-week high for NVNO is $30.80 and the 52-week low is $7.01. The stock is currently 73.5% below its high.